Dr. Christian Anton Thomas, MD

Dr. Thomas practices at New England Cancer Specialists in Scarborough, Maine.

Dr. Thomas' NPI, 1487651584, was assigned on July 5, 2005. Dr. Thomas holds Maine license MD19427.

Dr. Thomas' primary practice is New England Cancer Specialists, at 100 Campus Dr, Scarborough, ME 04074 in Cumberland County. The practice phone is (207) 303-3000.

Dr. Thomas' primary practice is New England Cancer Specialists in Scarborough, Maine. Dr. Thomas is also affiliated with MaineHealth Maine Medical Center. The medical group on file is New England Cancer Specialists. Dmand AI also links Dr. Thomas to 4 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Thomas practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Thomas' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Thomas' licenses on file in 2 states: Maine and New Hampshire.

CMS data shows 78,491 Medicare services from Dr. Thomas across 54 procedure codes in 2024, for 492 Medicare patients. Medicare paid $1,398,209 for them. Every service was in an office.

CMS counts 492 Medicare patients who saw Dr. Thomas in 2024. The largest group is 65 to 74, with 192 patients. 73% of them have high blood pressure, and 70% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Thomas' median patient age at 71, with 46% women.

In 2024, Dr. Thomas wrote 2,379 Medicare Part D claims for 284 patients. 51% of them were for generic drugs. CMS names the drug for 2,183 of them, across 32 drugs with 11 or more claims each, at $12,282,075 in total drug cost. In 2023, CMS named 2,041 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Thomas for performance year 2024, reported through an alternative payment model (APM). Dr. Thomas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Thomas as offering telehealth.

Dmand AI links 17 papers to Dr. Thomas, published from 2014 to 2024. 2021 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms and Antibodies, Monoclonal, Humanized. Dr. Thomas has published most often in Case Rep Oncol. Dr. Thomas' most frequent co-authors are Jens Rueter, MD, Gene G. Finley, MD and Robert Matthew Jotte, MD.

Dmand AI links Dr. Thomas to 8 clinical trials, 2 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Melanoma. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 202 general payments to Dr. Thomas from 39 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Genentech, Inc. paid the most, $37,873. It also lists 9 research payments totaling $4,121 from 2020 to 2021.